A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.

Trial Profile

A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs CV 8102 (Primary) ; HepaVac 101 (Primary) ; Cyclophosphamide
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 26 Sep 2017 New source identified and integrated (European Clinical Trials Database; EudraCT2015-003389-10).
    • 20 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 13 Sep 2017 Planned initiation date changed from 15 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top